Three years ago, Roche sent shockwaves ricocheting through the R&D field when it decided to write off a half-billion dollar initiative in RNA drug research and sell off its dedicated facility in Wisconsin. But a year after John Reed took over at Roche's Basel-based research group pRED, Roche is once again doing RNA deals.
Santaris Pharma has found another major pharma partner for its RNA drug platform. Bristol-Myers Squibb has forked over $10 million initially and promised much more to collaborate with Santaris on discovery and development of new genetic therapies.
The New England Journal of Medicine published data from a promising mid-stage study of Santaris Pharma's microRNA therapy against hepatitis C, bringing media attention to this unique method of combating the liver-damaging virus as most of the focus in the field is on new oral antiviral drugs.